This got published in NEJM imo because of this sta

This got published in NEJM imo because of this statement about drying up hidden reservoirs. I've looked UB-421 before, but didn't consider it a threat using an IV. It has the similar method of action to leronlimab binding to receptors

So my question. Has cydy checked the hidden reservoirs with leronlimab? If UB-421 is lowering the reservoirs, I see no reason leronlimab would not do that same thing.

Quote:

---

What's more, early results suggest that UB-421 may also be able to dry up hidden reservoirs of HIV that HAART can't reach.

This still needs to be replicated in a larger trial, Wang cautioned. But if confirmed, it would essentially amount to a "functional cure," she added.

---

https://www.usnews.com/news/health-news/artic...iv-therapy

Quote:

---

"So, there have been a number of studies using different kinds of antibodies that you transfer into someone intermittently, to see if you can keep the virus suppressed below a detectable level," he said.

"But this study was very interesting," Fauci said, "because the antibody they use is not directed at the virus itself, but at the receptors that the virus binds to. It's directed against the host cell, which is unique."

---